Related Experiment Video
Updated: Jun 18, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Advances from targeted therapy for non-metastatic HER2-positive inflammatory breast cancer
Jessica A Steadman1, Tina J Hieken1
1Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Abstract:
Among inflammatory breast cancer (IBC) patients, over one-third have HER2-overexpressing (HER2+) tumors. Pathologic complete response (pCR) rates to neoadjuvant targeted and chemotherapy for patients with HER2+ non-metastatic IBC now apporach 60% and favorable long-term survival rates are being reported for those with a pCR. Immune mechanisms contributing to this phenomenon include antibody-mediated immune activation and induction of memory T-cell reponses which may explain the sustained antitumor response seen after discontinuation of targeted therapies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Tumor Immunotherapy

